Manufacturing of AAV vectors: translational challenges from development to industrialisation
- 10 November 2021
- journal article
- research article
- Published by Portland Press Ltd. in Emerging Topics in Life Sciences
- Vol. 5 (5) , 725-728
Abstract
AAV mediated gene therapy offers the potential for curative therapies for many fatal and debilitating diseases, however the translation of these concepts into licenced products is stymied by manufacturing challenges leading to very high costs and delayed commercialisation. This is an issue which vector developers need to address, specifically around productivities and vector purities including levels of empty non-functional capsids. To date vector developers have focused on the optimising of vector targeting and gene delivery, however there is an increasing need to recognise the issue of manufacturability of vectors, and to be able develop screening and assessment of novel vectors to ensure that in future innovations and development can be produced to the required quality and in the desired quantities and at an acceptable cost.Keywords
This publication has 8 references indexed in Scilit:
- Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapiesMolecular Therapy - Methods & Clinical Development, 2021
- The clinical landscape for AAV gene therapiesNature Reviews Drug Discovery, 2021
- Advancements in molecular design and bioprocessing of recombinant adeno‐associated virus gene delivery vectors using the insect‐cell baculovirus expression platformBiotechnology Journal, 2020
- Current challenges in biotherapeutic particles manufacturingExpert Opinion on Biological Therapy, 2019
- Viral vector manufacturing: how to address current and future demands?Cell & Gene Therapy Insights, 2019
- Overcoming Bottlenecks in AAV Manufacturing for Gene TherapyCell & Gene Therapy Insights, 2018
- Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced DosesHuman Gene Therapy Methods, 2016
- Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effectsMolecular Therapy - Methods & Clinical Development, 2014